A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Sponsor: Bristol-Myers Squibb

Sponsor score: 60

ClinicalTrials ID:NCT06618287

This clinical trial assesses the safety, tolerability, and preliminary efficacy of BMS-986507 in combination with Osimertinib and Pembrolizumab in adults with advanced solid tumors. Participants receive specified doses of these drugs on designated days. Eligibility criteria focus on adults with advanced solid tumors, ensuring a targeted evaluation of the drug combinations.

Patient Parameters

Program Overview

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.

Eligibility Criteria

Inclusion Criteria

  • Participants must have at least one measurable lesion per response evaluation criteria in solid tumors.
  • Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
  • Participants must have a life expectancy of at least 3 months at the time of the first dose.

Exclusion Criteria

  • Participants must not have any mixed Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) histology.
  • Participants must not have any untreated symptomatic central nervous system (CNS) metastases.
  • Participants must not have a history of serious recurrent infections.
  • Participants must not have a history of severe heart disease.
  • Other protocol-defined Inclusion/Exclusion criteria apply.

Locations

FACILITYZIPCITYSTATE
Local Institution - 000933136MiamiFlorida
John Theurer Cancer Center at Hackensack University Medical Center07601HackensackNew Jersey
Local Institution - 002944195ClevelandOhio
Local Institution - 001415232PittsburghPennsylvania
Local Institution - 001298104SeattleWashington

Get This Program In Your Inbox

You can sign up and apply your patients for this program.